BioArctics Q3 Results Showcase Growth: Leqembi Royalties Drive Positive Share MovementBioArctic, a Swedish biopharmaceutical company, saw its shares surge by over six percent following the release of its Q3 results. The company met expectations and reported a smaller operating loss than anticipated, largely due to increased royalty revenue from its Alzheimers treatment, Leqembi.Leqembi royalties contributed to one hundred seventeen million Swedish Kronor in net revenues for the quarter, with significant growth in sales in the US and Japan. Excluding a one-time stocking effect in China, Leqembi sales grew by fourteen percent compared to the previous quarter.Over the first nine months of the year, Leqembi-related royalties reached three hundred seventy-six million Swedish Kronor, marking a substantial increase of over one hundred eighty percent compared to the same period last year. BioArctics operating loss for the quarter was twenty-nine million Swedish Kronor, much better than the predicted fifty-nine million Swedish Kronor loss.The company also recognized eight point five million Swedish Kronor from a Novartis agreement, supporting its strategy to expand its BrainTransporter technology platform. As of September thirtieth, BioArctic reported a strong cash balance of one point eight eight billion Swedish Kronor. RBC Capital Markets maintained its outperform rating on BioArctic, reflecting the companys consistent performance and improving financial metrics.

The Daily News Now! — Every city. Every story. AI-powered.

---

Hosted on Acast. See acast.com/privacy for more information.